Opinion|Videos|July 17, 2024
Differentiating Clinical Markers in Vitiligo: Managing Unstable Disease and Depigmented Macules
Author(s)Andrew F. Alexis, MD, MPH
An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is your impression of this case?
- What challenges does this case present with, if any?
- What considerations should be taken into account when treating a patient with worsening vitiligo involving large BSA?
- In your clinical practice, what role does the amount of BSA coverage play in your treatment decisions?
- Are there BSA limits you adhere to when treating patients with widespread vitiligo?
- What is your approach to the patient with worsening vitiligo that involves high BSA?
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
5